Obayashi to Acquire Multiplex in $526M Expansion Deal 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
SAN DIEGO, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overview at the Biotech Showcase 2016 conference on Monday, January 11, 2016 at 3:00 p.m. PT (6:00 p.m. ET) in San Francisco.
A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website for 30 days after the conference.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Jesse Baumgartner, Stern Investor Relations, Inc. 212.362.1200, [email protected]
